Moderna raised its 2026 revenue-growth forecast to 15–25%, citing international COVID-19 vaccine demand and partnership payments, and reported third-quarter revenue of approximately $1.3 billion. Investor attention remains focused on intismeran autogene, its individualized cancer vaccine developed with Merck & Co.; previously reported late-stage findings indicated a 42% reduction in melanoma recurrence or death when combined with Keytruda, but those findings are not new November 6 data. Moderna is targeting a U.S. regulatory submission in 2026 and potential launch in 2027. Separately, the company decided not to add another cohort to its investigational norovirus vaccine study this season after an interim analysis did not meet the prespecified threshold for early success.
Reuters
Source: Reuters, November 6
Why it matters strategically
Moderna faces an important capital-allocation problem: balancing a commercially established but variable vaccine business against potentially valuable oncology programs requiring further clinical and regulatory investment.
A positive melanoma signal can support development, but it does not establish the final probability of approval, reimbursement, or profitable commercialization.
